Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | DGKA | P23743 | 1/20 | 0.40 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284647 | 0.90 | ALDH1A1 (0.50) | CA2CA1CPB2ALDH1A1MEN1 | |
| SCHEMBL3682929 | 0.89 | CA2 (0.62) | CA2CA1MAPK1CPB2ZDHHC7 | |
| SCHEMBL12860221 | 0.89 | CA2 (0.62) | CA2CA1MAPK1CPB2ZDHHC7 | |
| SCHEMBL12860453 | 0.89 | CA2 (0.62) | CA2CA1MAPK1CPB2ZDHHC7 | |
| SCHEMBL4957929 | 0.87 | ALDH1A1 (0.48) | CA2CA1CPB2ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL27554398 | 0.87 | ALDH1A1 (0.48) | CA2CA1CPB2ALDH1A1MEN1 | |
| SCHEMBL21981164 | 0.87 | ALDH1A1 (0.48) | CA2CA1CPB2ALDH1A1MEN1 | |
| SCHEMBL28145904 | 0.87 | ALDH1A1 (0.48) | CA2CA1CPB2ALDH1A1MEN1 | |
| SCHEMBL29207090 | 0.87 | ALDH1A1 (0.48) | CA2CA1CPB2ALDH1A1MEN1 | |
| SCHEMBL28904001 | 0.87 | ALDH1A1 (0.48) | CA2CA1CPB2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569917-B1 | PYRAZINE-BASED TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2016-12-07 | — | — | EP | disclosed |
| US-8084456-B2 | Pyrazine-based tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-12-27 | — | — | US | disclosed |
| EP-1569917-A4 | PYRAZINE-BASED TUBULIN INHIBITORS | CYTOPIA PTY LTD (AU) | 2007-08-15 | — | — | EP | disclosed |
| US-20070082894-A1 | Pyrazine-based tubulin inhibitors | CYTOPIA PTY LTD (AU) | 2007-04-12 | — | — | US | disclosed |
| EP-1569917-A1 | PYRAZINE-BASED TUBULIN INHIBITORS | Cytopia PTY Ltd (AU) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004052868-A1 | PYRAZINE-BASED TUBULIN INHIBITORS | CYTOPIA PTY LTD (AU) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082894-A1 | Pyrazine-based tubulin inhibitors | TUBB1, TUBA1C, TUBB | CA2 3412/4885CA1 2778/4885MAPK1 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.